U.S. Joint Pain Injections Market to Grow at a CAGR of 9.58% During 2025-2032; Availability of a Variety of Injectables for Therapy to Bolster Market Growth

The U.S. joint pain injections market size was valued at USD 2.32 billion in 2024. The market is projected to grow from USD 2.51 billion in 2025 to USD 4.76 billion by 2032, exhibiting a CAGR of 9.58% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, "U.S. Joint Pain Injections Market Size, Share & Industry Analysis, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, and Others), By Joint Type (Knee, Hip, Hand & Wrist, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2025-2032”

In order to alleviate pain, joint pain injections are typically given intra-articularly at the joint location. It is used to treat to knee, hip, hand and wrist, and shoulder joint discomfort. The country’s aging population, rheumatoid arthritis, and osteoarthritis are all becoming more common, and the availability of a variety of injectables for therapy is anticipated to support market expansion.

For instance, the U.S. Food and Drug Administration (FDA) sent SEIKAGAKU CORPORATION a full response letter (CRL) for the Biologics License Application (BLA) for SI-6603 condoliase in March 2025. Leg pain brought on by lumbar disc herniation is lessened by this treatment.

An Increase in Site Operation through Collaboration to Satisfy Growing Market Demand

• July 2025: Sanofi and Thermo Fisher Scientific Inc. collaborated to support the production of pharmaceutical products in the U.S. The alliance intends to increase the site’s operations and satisfy growing demand for U.S. production capacity from pharmaceutical and biotech clients.

Growing Incidences of Osteoarthritis to Drive Market Growth

One of the main drivers propelling the U.S. joint pain injections market growth is the increasing incidence of osteoarthritis, which causes joint pain. Growing older populations and changing lifestyles raise the risk of obesity and musculoskeletal conditions. As a result, joint pain injections lessen the need for surgery and the pain it causes.

However, availability of alternative treatments for joint pain, hamper market growth.

Key Players to Emphasize on R&D and Innovation in Products to Boost Market Growth

The U.S. joint pain injections is characterized by a fragmented competitive structure, with multiple companies operating with a broad range of products and a significant presence in the country. Due to its strong presence and wide range of products, Sanofi maintained a commanding share of the market in terms of competition. Additionally, with strong emphasis on research and development Bioventus Inc., Zimmer Biomet, Ferring, and Dr. Reddy’s Laboratories Ltd. provide a complete robust, and cutting-edge product. With their product lines of corticosteroid injections and hyaluronic acid injections, the other companies, such as Pacira and Anika Therapeutics, Inc., among others, controlled a sizable portion of the U.S. market.

Notable Industry Development

• July 2025: In order to increase the U.S. joint pain injections market share of ZILRETTA, an injectable for arthritic knee pain, Pacira Pharmaceuticals, Inc. formed a strategic agreement with Johnson & Jhonson MedTech. Through this partnership, businesses hope to increase access to a sizable portion of roughly seven million intra-articulator knee injections administered in the U.S. each year.

List of the Companies Profiled in the Report

• Dr. Reddy’s Laboratories Ltd. (India)
• Sanofi (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Zimmer Biomet (U.S.)
• Anika Therapeutics, Inc. (U.S.)
• Ferring (Switzerland)
• Bioventus Inc. (U.S.)
• SEIKAGAKU CORPORATION (Japan)
• Pacira Pharmaceuticals, Inc. (U.S.)
• Fidia Farmaceutici S.p.A. (Italy)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/u-s-joint-pain-injections-market-108119

Further Report Findings

• Based on product segment, in 2024, the segment with the biggest market share for U.S. joint pain injections was hyaluronic acid injections. Due to the rising incidence of osteoarthritis in the U.S. and the therapeutic advantages of hyaluronic acid injections, patients with osteoarthritis are increasingly adopting and using this product. The segment’s expansion in the market is also being driven by growing partnerships among important players to provide sufficient coverage for improved patient outcomes. For instance, in December 2023, Bioventus Inge executed a partnership with Aetna Medicare Advantage plans to provide DUROLANE as a benefit for treating knee osteoarthritis (OA)
• Based on joint type segment, the largest market share was held by the knee segment. With 43.5% share, the segment is expected to dominate in 2025. The growing number of individuals in the nation experiencing knee pain is responsible for the segment’s leading share.
• Based on distribution channel segment, the market share was dominated by the retail pharmacies segment in 2024. In 2025, the segment’s share is expected to be 80.7%. Convenience and the growing number of retail pharmacies in the nation are driving the distribution of joint paint injections through retail channels, which is anticipated to accelerate the segment’s market expansion.

Table of Segmentation